

Mauro Delorenzi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1259832/publications.pdf>

Version: 2024-02-01

149
papers

27,378
citations

13827

67
h-index

9553

142
g-index

153
all docs

153
docs citations

153
times ranked

38122
citing authors

#	ARTICLE	IF	CITATIONS
1	Shared acute phase traits in effector and memory human CD8 T cells. <i>Current Research in Immunology</i> , 2022, 3, 1-12.	1.2	2
2	Apelin-driven endothelial cell migration sustains intestinal progenitor cells and tumor growth. , 2022, 1, 476-490.		13
3	ADAMTS18+ villus tip telocytes maintain a polarized VEGFA signaling domain and fenestrations in nutrient-absorbing intestinal blood vessels. <i>Nature Communications</i> , 2022, 13, .	5.8	20
4	Gain of HIF1 Activity and Loss of miRNA <i>let-7d</i> Promote Breast Cancer Metastasis to the Brain via the PDGF/PDGFR Axis. <i>Cancer Research</i> , 2021, 81, 594-605.	0.4	18
5	Blood-brain barrier alterations in human brain tumors revealed by genome-wide transcriptomic profiling. <i>Neuro-Oncology</i> , 2021, 23, 2095-2106.	0.6	23
6	Microglia control small vessel calcification via TREM2. <i>Science Advances</i> , 2021, 7, .	4.7	22
7	Pericytes regulate vascular immune homeostasis in the CNS. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	86
8	70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age. <i>Lancet Oncology</i> , The, 2021, 22, 476-488.	5.1	179
9	Transcriptomic Signature Differences Between SARS-CoV-2 and Influenza Virus Infected Patients. <i>Frontiers in Immunology</i> , 2021, 12, 666163.	2.2	27
10	BET inhibitors repress expression of interferon-stimulated genes and synergize with HDAC inhibitors in glioblastoma. <i>Neuro-Oncology</i> , 2021, 23, 1680-1692.	0.6	17
11	Cell-autonomous inflammation of BRCA1-deficient ovarian cancers drives both tumor-intrinsic immunoreactivity and immune resistance via STING. <i>Cell Reports</i> , 2021, 36, 109412.	2.9	60
12	FOXC2 controls adult lymphatic endothelial specialization, function, and gut lymphatic barrier preventing multiorgan failure. <i>Science Advances</i> , 2021, 7, .	4.7	43
13	PD-1+Tcf1+CD8+T cells from established chronic infection can form memory while retaining a stable imprint of persistent antigen exposure. <i>Cell Reports</i> , 2021, 36, 109672.	2.9	8
14	Targeting OLFML3 in Colorectal Cancer Suppresses Tumor Growth and Angiogenesis, and Increases the Efficacy of Anti-PD1 Based Immunotherapy. <i>Cancers</i> , 2021, 13, 4625.	1.7	12
15	Tailoring the resolution of single-cell RNA sequencing for primary cytotoxic T cells. <i>Nature Communications</i> , 2021, 12, 569.	5.8	10
16	Inflammatory B cells correlate with failure to checkpoint blockade in melanoma patients. <i>Oncolmmunology</i> , 2021, 10, 1873585.	2.1	15
17	Myeloid antigen-presenting cell niches sustain antitumor T cells and license PD-1 blockade via CD28 costimulation. <i>Cancer Cell</i> , 2021, 39, 1623-1642.e20.	7.7	64
18	Lef1 restricts ectopic crypt formation and tumor cell growth in intestinal adenomas. <i>Science Advances</i> , 2021, 7, eabj0512.	4.7	6

#	ARTICLE	IF	CITATIONS
19	Neutrophils suppress tumor-infiltrating T cells in colon cancer via matrix metalloproteinase-mediated activation of TGF- β 2. <i>EMBO Molecular Medicine</i> , 2020, 12, e10681.	3.3	100
20	Central memory CD8+ T cells derive from stem-like Tcf7hi effector cells in the absence of cytotoxic differentiation. <i>Immunity</i> , 2020, 53, 985-1000.e11.	6.6	107
21	Controlling technical variation amongst 6693 patient microarrays of the randomized MINDACT trial. <i>Communications Biology</i> , 2020, 3, 397.	2.0	7
22	The Interleukin 22 Pathway Interacts with Mutant KRAS to Promote Poor Prognosis in Colon Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 4313-4325.	3.2	22
23	Antiangiogenic immunotherapy suppresses desmoplastic and chemoresistant intestinal tumors in mice. <i>Journal of Clinical Investigation</i> , 2020, 130, 1199-1216.	3.9	35
24	TOX reinforces the phenotype and longevity of exhausted T cells in chronic viral infection. <i>Nature</i> , 2019, 571, 265-269.	13.7	581
25	Endothelial Calcineurin Signaling Restrains Metastatic Outgrowth by Regulating Bmp2. <i>Cell Reports</i> , 2019, 26, 1227-1241.e6.	2.9	15
26	Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors. <i>Cancer Cell</i> , 2019, 35, 885-900.e10.	7.7	475
27	Systemic and central nervous system metabolic alterations in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 93.	3.0	143
28	Prospective validation in epithelial tumors of a gene expression predictor of liver metastasis derived from uveal melanoma. <i>Scientific Reports</i> , 2019, 9, 17178.	1.6	3
29	Differential regulation of RNA polymerase III genes during liver regeneration. <i>Nucleic Acids Research</i> , 2019, 47, 1786-1796.	6.5	12
30	Type I interferon/IRF7 axis instigates chemotherapy-induced immunological dormancy in breast cancer. <i>Oncogene</i> , 2019, 38, 2814-2829.	2.6	85
31	RasGRP1 is a potential biomarker for stratifying anti-EGFR therapy response in colorectal cancer. <i>JCI Insight</i> , 2019, 4, .	2.3	17
32	The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033. <i>Acta Neuropathologica</i> , 2018, 135, 601-615.	3.9	76
33	Context-based retrieval of functional modules in protein-protein interaction networks. <i>Briefings in Bioinformatics</i> , 2018, 19, 995-1007.	3.2	6
34	The transcription factor Rfx7 limits metabolism of NK cells and promotes their maintenance and immunity. <i>Nature Immunology</i> , 2018, 19, 809-820.	7.0	42
35	Comprehensive Genomic Profiling of Patient-matched Head and Neck Cancer Cells: A Preclinical Pipeline for Metastatic and Recurrent Disease. <i>Molecular Cancer Research</i> , 2018, 16, 1912-1926.	1.5	22
36	Modulation of the peripheral blood transcriptome by the ingestion of probiotic yoghurt and acidified milk in healthy, young men. <i>PLoS ONE</i> , 2018, 13, e0192947.	1.1	40

#	ARTICLE	IF	CITATIONS
37	Clinical and pharmacogenetic determinants of 5-fluorouracyl/leucovorin/irinotecan toxicity: Results of the PETACC-3 trial. <i>European Journal of Cancer</i> , 2018, 99, 66-77.	1.3	16
38	<i>BRAF</i> V600E Mutant Colorectal Cancer Subtypes Based on Gene Expression. <i>Clinical Cancer Research</i> , 2017, 23, 104-115.	3.2	167
39	Integrative clinicopathological and molecular analyses of angioimmunoblastic T-cell lymphoma and other nodal lymphomas of follicular helper T-cell origin. <i>Haematologica</i> , 2017, 102, e148-e151.	1.7	163
40	Broad and Conserved Immune Regulation by Genetically Heterogeneous Melanoma Cells. <i>Cancer Research</i> , 2017, 77, 1623-1636.	0.4	13
41	Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia. <i>Blood</i> , 2017, 129, e26-e37.	0.6	195
42	RIP4 inhibits STAT3 signaling to sustain lung adenocarcinoma differentiation. <i>Cell Death and Differentiation</i> , 2017, 24, 1761-1771.	5.0	26
43	Caloric dose-responsive genes in blood cells differentiate the metabolic status of obese men. <i>Journal of Nutritional Biochemistry</i> , 2017, 43, 156-165.	1.9	11
44	Mutant <i>CTNNB1</i> and histological heterogeneity define metabolic subtypes of hepatoblastoma. <i>EMBO Molecular Medicine</i> , 2017, 9, 1589-1604.	3.3	38
45	Increased ex vivo antigen presentation profile of B cells in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2017, 23, 802-809.	1.4	36
46	A Well-Controlled Experimental System to Study Interactions of Cytotoxic T Lymphocytes with Tumor Cells. <i>Frontiers in Immunology</i> , 2016, 7, 326.	2.2	22
47	A Vulnerability of a Subset of Colon Cancers with Potential Clinical Utility. <i>Cell</i> , 2016, 165, 317-330.	13.5	70
48	Comparison between direct and reverse electroporation of cells in situ: a simulation study. <i>Physiological Reports</i> , 2016, 4, e12673.	0.7	7
49	Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study. <i>The Lancet Gastroenterology and Hepatology</i> , 2016, 1, 207-216.	3.7	227
50	70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. <i>New England Journal of Medicine</i> , 2016, 375, 717-729.	13.9	1,427
51	Activating mutations in genes related to TCR signaling in angioimmunoblastic and other follicular helper T-cell-derived lymphomas. <i>Blood</i> , 2016, 128, 1490-1502.	0.6	255
52	High antigen levels induce an exhausted phenotype in a chronic infection without impairing T cell expansion and survival. <i>Journal of Experimental Medicine</i> , 2016, 213, 1819-1834.	4.2	137
53	Modulation of mTOR Signalling Triggers the Formation of Stem Cell-like Memory T Cells. <i>EBioMedicine</i> , 2016, 4, 50-61.	2.7	89
54	DNA Topoisomerase I Gene Copy Number and mRNA Expression Assessed as Predictive Biomarkers for Adjuvant Irinotecan in Stage II/III Colon Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 1621-1631.	3.2	13

#	ARTICLE	IF	CITATIONS
55	Reduced Expression of SMAD4 Is Associated with Poor Survival in Colon Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 3037-3047.	3.2	56
56	Sensitivity Analysis of the MGMT-STP27 Model and Impact of Genetic and Epigenetic Context to Predict the MGMT Methylation Status in Gliomas and Other Tumors. <i>Journal of Molecular Diagnostics</i> , 2016, 18, 350-361.	1.2	90
57	A Composite Gene Expression Signature Optimizes Prediction of Colorectal Cancer Metastasis and Outcome. <i>Clinical Cancer Research</i> , 2016, 22, 734-745.	3.2	43
58	Cell Line Derived 5-FU and Irinotecan Drug-Sensitivity Profiles Evaluated in Adjuvant Colon Cancer Trial Data. <i>PLoS ONE</i> , 2016, 11, e0155123.	1.1	6
59	A 12-gene signature to distinguish colon cancer patients with better clinical outcome following treatment with 5-fluorouracil or FOLFIRI. <i>Journal of Pathology: Clinical Research</i> , 2015, 1, 160-172.	1.3	8
60	Genome-wide RNA profiling of long-lasting stem cell-like memory CD8 T cells induced by Yellow Fever vaccination in humans. <i>Genomics Data</i> , 2015, 5, 297-301.	1.3	11
61	BCL9/9L- β -catenin Signaling is Associated With Poor Outcome in Colorectal Cancer. <i>EBioMedicine</i> , 2015, 2, 1932-1943.	2.7	58
62	Genomics and drug profiling of fatal TCF3-HLF ⁺ positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options. <i>Nature Genetics</i> , 2015, 47, 1020-1029.	9.4	190
63	Response. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv056-djv056.	3.0	0
64	Establishment and characterization of models of chemotherapy resistance in colorectal cancer: Towards a predictive signature of chemoresistance. <i>Molecular Oncology</i> , 2015, 9, 1169-1185.	2.1	91
65	Long-lasting stem cell-like memory CD8 ⁺ T cells with a naïve-like profile upon yellow fever vaccination. <i>Science Translational Medicine</i> , 2015, 7, 282ra48.	5.8	174
66	Clinical Application of Prognostic Gene Expression Signature in Fusion Gene-Negative Rhabdomyosarcoma: A Report from the Children's Oncology Group. <i>Clinical Cancer Research</i> , 2015, 21, 4733-4739.	3.2	21
67	The consensus molecular subtypes of colorectal cancer. <i>Nature Medicine</i> , 2015, 21, 1350-1356.	15.2	3,596
68	Molecular Markers Identify Subtypes of Stage III Colon Cancer Associated With Patient Outcomes. <i>Gastroenterology</i> , 2015, 148, 88-99.	0.6	273
69	FOXC2 and fluid shear stress stabilize postnatal lymphatic vasculature. <i>Journal of Clinical Investigation</i> , 2015, 125, 3861-3877.	3.9	186
70	Drug Response Profiling to Identify Selective Pharmacological Activity in Drug Resistant ALL. <i>Blood</i> , 2015, 126, 2532-2532.	0.6	0
71	miR-345 in Metastatic Colorectal Cancer: A Non-Invasive Biomarker for Clinical Outcome in Non-KRAS Mutant Patients Treated with 3rd Line Cetuximab and Irinotecan. <i>PLoS ONE</i> , 2014, 9, e99886.	1.1	68
72	The Molecular Signature of the Stroma Response in Prostate Cancer-Induced Osteoblastic Bone Metastasis Highlights Expansion of Hematopoietic and Prostate Epithelial Stem Cell Niches. <i>PLoS ONE</i> , 2014, 9, e114530.	1.1	42

#	ARTICLE	IF	CITATIONS
73	Quantifying ChIP-seq data: a spiking method providing an internal reference for sample-to-sample normalization. <i>Genome Research</i> , 2014, 24, 1157-1168.	2.4	143
74	Fifteen years SIB Swiss Institute of Bioinformatics: life science databases, tools and support. <i>Nucleic Acids Research</i> , 2014, 42, W436-W441.	6.5	13
75	Cross-species analysis of genetically engineered mouse models of MAPK driven colorectal cancer identifies hallmarks of human disease. <i>DMM Disease Models and Mechanisms</i> , 2014, 7, 613-23.	1.2	5
76	PROX1 Promotes Metabolic Adaptation and Fuels Outgrowth of Wnt high Metastatic Colon Cancer Cells. <i>Cell Reports</i> , 2014, 8, 1957-1973.	2.9	66
77	Test of Four Colon Cancer Risk-Scores in Formalin Fixed Paraffin Embedded Microarray Gene Expression Data. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	3.0	30
78	Cancer cellâ€™autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. <i>Nature Medicine</i> , 2014, 20, 1301-1309.	15.2	823
79	The Hippo Transducer YAP1 Transforms Activated Satellite Cells and Is a Potent Effector of Embryonal Rhabdomyosarcoma Formation. <i>Cancer Cell</i> , 2014, 26, 273-287.	7.7	152
80	Immunohistochemistry as a valuable tool to assess CD30 expression in peripheral T-cell lymphomas: high correlation with mRNA levels. <i>Blood</i> , 2014, 124, 2983-2986.	0.6	89
81	Batch Effect Confounding Leads to Strong Bias in Performance Estimates Obtained by Cross-Validation. <i>PLoS ONE</i> , 2014, 9, e100335.	1.1	46
82	Towards an environment for data mining based analysis processes in bioinformatics and personalized medicine. <i>Network Modeling Analysis in Health Informatics and Bioinformatics</i> , 2013, 2, 29-44.	1.2	7
83	Context-dependent interpretation of the prognostic value of BRAF and KRAS mutations in colorectal cancer. <i>BMC Cancer</i> , 2013, 13, 439.	1.1	37
84	DUSP 4 expression identifies a subset of colorectal cancer tumors that differ in MAPK activation, regardless of the genotype. <i>Biomarkers</i> , 2013, 18, 516-524.	0.9	26
85	Gene expression patterns unveil a new level of molecular heterogeneity in colorectal cancer. <i>Journal of Pathology</i> , 2013, 231, 63-76.	2.1	331
86	Phosphorylation Regulates FOXC2-Mediated Transcription in Lymphatic Endothelial Cells. <i>Molecular and Cellular Biology</i> , 2013, 33, 3749-3761.	1.1	48
87	BRAF and KRAS mutations as additional risk factors in the context of clinical parameters of patients with colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, 3522-3522.	0.8	1
88	Proximal and distal colon tumors as distinct biologic entities with different prognoses.. <i>Journal of Clinical Oncology</i> , 2013, 31, 3526-3526.	0.8	13
89	Identification of synthetic lethal interactions with the BRAF oncogene in colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, 403-403.	0.8	0
90	Microarray gene expression study of the RESPECT trial for the identification of prognostic and predictive markers.. <i>Journal of Clinical Oncology</i> , 2013, 31, e14561-e14561.	0.8	0

#	ARTICLE	IF	CITATIONS
91	Thymidylate synthase (TS) expression as a prognostic molecular marker in stage II/III colon cancer.. Journal of Clinical Oncology, 2013, 31, 3577-3577.	0.8	1
92	Genome-Wide RNA Polymerase II Profiles and RNA Accumulation Reveal Kinetics of Transcription and Associated Epigenetic Changes During Diurnal Cycles. PLoS Biology, 2012, 10, e1001442.	2.6	178
93	DNA fingerprinting of glioma cell lines and considerations on similarity measurements. Neuro-Oncology, 2012, 14, 701-711.	0.6	46
94	A multiplicity of factors contributes to selective RNA polymerase III occupancy of a subset of RNA polymerase III genes in mouse liver. Genome Research, 2012, 22, 666-680.	2.4	56
95	Characterization and Clinical Evaluation of CD10+ Stroma Cells in the Breast Cancer Microenvironment. Clinical Cancer Research, 2012, 18, 1004-1014.	3.2	46
96	Identification of a Poor-Prognosis BRAF-Mutant-Like Population of Patients With Colon Cancer. Journal of Clinical Oncology, 2012, 30, 1288-1295.	0.8	191
97	microRNAs in colon cancer: A roadmap for discovery. FEBS Letters, 2012, 586, 3000-3007.	1.3	30
98	A robust genomic signature for the detection of colorectal cancer patients with microsatellite instability phenotype and high mutation frequency. Journal of Pathology, 2012, 228, 586-595.	2.1	55
99	MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status. Acta Neuropathologica, 2012, 124, 547-560.	3.9	274
100	Integrated Analysis of Molecular and Clinical Prognostic Factors in Stage II/III Colon Cancer. Journal of the National Cancer Institute, 2012, 104, 1635-1646.	3.0	227
101	PAX3/FOXO1 Fusion Gene Status Is the Key Prognostic Molecular Marker in Rhabdomyosarcoma and Significantly Improves Current Risk Stratification. Journal of Clinical Oncology, 2012, 30, 1670-1677.	0.8	297
102	Molecular and clinicopathologic evidence of heterogeneity in KRAS-mutant colon cancers.. Journal of Clinical Oncology, 2012, 30, 3575-3575.	0.8	1
103	Validation of two gene-expression risk scores in a large colon cancer cohort and contribution to an improved prognostic method.. Journal of Clinical Oncology, 2012, 30, 3509-3509.	0.8	2
104	Identification and validation of gene expression subtypes in a large set of colorectal cancer samples.. Journal of Clinical Oncology, 2012, 30, 3511-3511.	0.8	3
105	Development of prognostic molecular markers in pediatric rhabdomyosarcoma based on gene expression and copy number variations.. Journal of Clinical Oncology, 2012, 30, 9510-9510.	0.8	0
106	Identification of Prognostic Molecular Features in the Reactive Stroma of Human Breast and Prostate Cancer. PLoS ONE, 2011, 6, e18640.	1.1	140
107	Detecting Epistasis with Restricted Response Patterns in Pairs of Biallelic Loci. Annals of Human Genetics, 2011, 75, 133-145.	0.3	2
108	The Wnt inhibitory factor 1 (WIF1) is targeted in glioblastoma and has a tumor suppressing function potentially by induction of senescence. Neuro-Oncology, 2011, 13, 736-747.	0.6	92

#	ARTICLE	IF	CITATIONS
109	Microsatellite Instability, Prognosis and Drug Sensitivity of Stage II and III Colorectal Cancer: More Complexity to the Puzzle. <i>Journal of the National Cancer Institute</i> , 2011, 103, 841-844.	3.0	63
110	Pathway Analysis of Glioblastoma Tissue after Preoperative Treatment with the EGFR Tyrosine Kinase Inhibitor Gefitinibâ€”A Phase II Trial. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 1102-1112.	1.9	170
111	The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. <i>Nature Biotechnology</i> , 2010, 28, 827-838.	9.4	795
112	The effect of translocation-induced nuclear reorganization on gene expression. <i>Genome Research</i> , 2010, 20, 554-564.	2.4	100
113	Bcl9/Bcl9l Are Critical for Wnt-Mediated Regulation of Stem Cell Traits in Colon Epithelium and Adenocarcinomas. <i>Cancer Research</i> , 2010, 70, 6619-6628.	0.4	116
114	Prognostic and Predictive Biomarkers in Resected Colon Cancer: Current Status and Future Perspectives for Integrating Genomics into Biomarker Discovery. <i>Oncologist</i> , 2010, 15, 390-404.	1.9	155
115	Prognostic Role of <i>KRAS</i> and <i>BRAF</i> in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial. <i>Journal of Clinical Oncology</i> , 2010, 28, 466-474.	0.8	1,048
116	Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. <i>Lancet Oncology</i> , The, 2010, 11, 753-762.	5.1	1,915
117	Modulation of Angiogenic and Inflammatory Response in Glioblastoma by Hypoxia. <i>PLoS ONE</i> , 2009, 4, e5947.	1.1	95
118	FOXC2 controls formation and maturation of lymphatic collecting vessels through cooperation with NFATc1. <i>Journal of Cell Biology</i> , 2009, 185, 439-457.	2.3	295
119	Integrated Analysis of Gene Expression Profiling Studies â€” Examples in Breast Cancer. , 2009, , 85-114.		1
120	A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. <i>Nature Medicine</i> , 2009, 15, 68-74.	15.2	566
121	An integrated genetic and functional analysis of the role of type II transmembrane serine proteases (TMPRSSs) in hearing loss. <i>Human Mutation</i> , 2008, 29, 130-141.	1.1	70
122	Leukaemia cell lines are robust in vitro models â€” response to MacLeod & Drexler. <i>British Journal of Haematology</i> , 2008, 142, 138-141.	1.2	0
123	Comprehensive spatiotemporal transcriptomic analyses of the ganglionic eminences demonstrate the uniqueness of its caudal subdivision. <i>Molecular and Cellular Neurosciences</i> , 2008, 37, 845-856.	1.0	40
124	Validation of Real-Time Methylation-Specific PCR to Determine O6-Methylguanine-DNA Methyltransferase Gene Promoter Methylation in Glioma. <i>Journal of Molecular Diagnostics</i> , 2008, 10, 332-337.	1.2	168
125	Biological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular Subtypes. <i>Clinical Cancer Research</i> , 2008, 14, 5158-5165.	3.2	745
126	CYR61 and Î±VÎ²5 Integrin Cooperate to Promote Invasion and Metastasis of Tumors Growing in Preirradiated Stroma. <i>Cancer Research</i> , 2008, 68, 7323-7331.	0.4	109

#	ARTICLE	IF	CITATIONS
127	Definition of Clinically Distinct Molecular Subtypes in Estrogen Receptor-Positive Breast Carcinomas Through Genomic Grade. <i>Journal of Clinical Oncology</i> , 2007, 25, 1239-1246.	0.8	711
128	Analysis of potential transcriptomic biomarkers for Huntington's disease in peripheral blood. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 14424-14429.	3.3	120
129	Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage. <i>Human Molecular Genetics</i> , 2007, 16, 1845-1861.	1.4	304
130	Strong Time Dependence of the 76-Gene Prognostic Signature for Node-Negative Breast Cancer Patients in the TRANSBIG Multicenter Independent Validation Series. <i>Clinical Cancer Research</i> , 2007, 13, 3207-3214.	3.2	839
131	Natural Gene-Expression Variation in Down Syndrome Modulates the Outcome of Gene-Dosage Imbalance. <i>American Journal of Human Genetics</i> , 2007, 81, 252-263.	2.6	187
132	Regional and cellular gene expression changes in human Huntington's disease brain. <i>Human Molecular Genetics</i> , 2006, 15, 965-977.	1.4	696
133	Gene Expression Profiling in Breast Cancer: Understanding the Molecular Basis of Histologic Grade To Improve Prognosis. <i>Journal of the National Cancer Institute</i> , 2006, 98, 262-272.	3.0	1,824
134	Gene expression profiling reveals consistent differences between clinical samples of human leukaemias and their model cell lines. <i>British Journal of Haematology</i> , 2006, 135, 520-523.	1.2	13
135	Proteomics Fingerprinting of Phagosome Maturation and Evidence for the Role of a G1± during Uptake. <i>Molecular and Cellular Proteomics</i> , 2006, 5, 2228-2243.	2.5	88
136	Validation and Clinical Utility of a 70-Gene Prognostic Signature for Women With Node-Negative Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2006, 98, 1183-1192.	3.0	1,128
137	Increased Expression of Urokinase-Type Plasminogen Activator mRNA Determines Adverse Prognosis in ErbB2-Positive Primary Breast Cancer. <i>Journal of Clinical Oncology</i> , 2006, 24, 4245-4253.	0.8	63
138	Mechanisms Regulating the Proliferative Potential of Human CD8+ T Lymphocytes Overexpressing Telomerase. <i>Journal of Immunology</i> , 2006, 177, 3657-3668.	0.4	33
139	On ubiquitin ligases and cancer. <i>Human Mutation</i> , 2005, 25, 507-512.	1.1	8
140	An atlas of human gene expression from massively parallel signature sequencing (MPSS). <i>Genome Research</i> , 2005, 15, 1007-1014.	2.4	154
141	Transcript Profiling Suggests That Differential Metabolic Adaptation of Mice to a High Fat Diet Is Associated with Changes in Liver to Muscle Lipid Fluxes. <i>Journal of Biological Chemistry</i> , 2004, 279, 50743-50753.	1.6	77
142	The Serine Repeat Antigen (SERA) Gene Family Phylogeny in Plasmodium: The Impact of GC Content and Reconciliation of Gene and Species Trees. <i>Molecular Biology and Evolution</i> , 2004, 21, 2161-2171.	3.5	24
143	Ubiquitin ligases as cancer genes. <i>Nature Reviews Cancer</i> , 2004, 4, 654-654.	12.8	1
144	Enzymic, Phylogenetic, and Structural Characterization of the Unusual Papain-like Protease Domain of Plasmodium falciparum SERA5. <i>Journal of Biological Chemistry</i> , 2003, 278, 48169-48177.	1.6	81

#	ARTICLE	IF	CITATIONS
145	Classification of human astrocytic gliomas on the basis of gene expression: a correlated group of genes with angiogenic activity emerges as a strong predictor of subtypes. <i>Cancer Research</i> , 2003, 63, 6613-25.	0.4	196
146	A Subset of Plasmodium falciparum SERA Genes Are Expressed and Appear to Play an Important Role in the Erythrocytic Cycle. <i>Journal of Biological Chemistry</i> , 2002, 277, 47524-47532.	1.6	149
147	Genes for Glycosylphosphatidylinositol Toxin Biosynthesis in Plasmodium falciparum. <i>Infection and Immunity</i> , 2002, 70, 4510-4522.	1.0	58
148	Identification of Proteins from Plasmodium falciparum That Are Homologous to Reticulocyte Binding Proteins in Plasmodium vivax. <i>Infection and Immunity</i> , 2001, 69, 1084-1092.	1.0	123
149	Drosophila homoeotic genes encode transcriptional activators similar to mammalian OTF-2. <i>Nature</i> , 1988, 336, 598-601.	13.7	138